Pharmacokinetics and Safety of CT-P17 (40 Mg/0.4 Ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults.
Immunotherapy（2023）
关键词
adalimumab,biologics,biosimilar,CT-P17,immunogenicity,Japan,monoclonal antibodies,pharmacokinetics,phase I,safety
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要